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Abstract
Objectives: We investigated the association between mul-
timorbidity among patients hospitalised with COVID-19
and their subsequent risk of mortality. We also explored
the interaction between the presence of multimorbidity
and the requirement for an individual to shield due to
the presence of specific conditions and its association
with mortality.
Design: We created a cohort of patients hospitalised in
Scotland due to COVID-19 during the first wave (between
28 February 2020 and 22 September 2020) of the pan-
demic. We identified the level of multimorbidity for the
patient on admission and used logistic regression to analyse
the association between multimorbidity and risk of mortal-
ity among patients hospitalised with COVID-19.
Setting: Scotland, UK.
Participants: Patients hospitalised due to COVID-19.
Main outcome measures: Mortality as recorded on
National Records of Scotland death certificate and being
coded for COVID-19 on the death certificate or death
within 28 days of a positive COVID-19 test.
Results: Almost 58% of patients admitted to the hospital
due to COVID-19 had multimorbidity. Adjusting for con-
founding factors of age, sex, social class and presence in the
shielding group, multimorbidity was significantly associated
with mortality (adjusted odds ratio 1.48, 95%CI 1.26–1.75).
The presence of multimorbidity and presence in the shield-
ing patients list were independently associated with mor-
tality but there was no multiplicative effect of having both
(adjusted odds ratio 0.91, 95%CI 0.64–1.29).
Conclusions: Multimorbidity is an independent risk factor
of mortality among individuals who were hospitalised due
to COVID-19. Individuals with multimorbidity could be
prioritised when making preventive policies, for example,
by expanding shielding advice to this group and prioritising
them for vaccination.
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Introduction
As of 9 June 2021, severe illness among the patients
infected with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has led to more than
3.5 million deaths1 across the globe, including almost
128,000 deaths in the UK. Although at this point in
time, vaccination programmes have successfully been
rolled out in a majority of rich countries leading to a
significant reduction in the number of cases and fatal-
ities,2,3 most of the population around the world
remains unvaccinated and still at risk.4 Until vaccines
are not widely distributed, it is crucial that we con-
tinue researching and reporting on what are the fac-
tors associated with worse outcomes to allow
mitigation strategies and adequate protection of
those deemed vulnerable to be provided.
It is known that almost 15% of individuals infected
with SARS-CoV-2 need hospitalisation and mortality
is reported among 30% of hospitalised patients.5,6
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There is evidence from previous work showing that the
risk of severe outcomes increases with different factors,
including increasing age age,7 male sex8 and the pres-
ence of specific pre-existing long-term conditions (such
as hypertension, diabetes or chronic kidney disease,
etc.).9–11 Multimorbidity (defined as two or more
long-term conditions) is strongly associated with age
and is very prevalent in both high- and low-middle
income countries.12 The importance and impact of
multimorbidity on subsequent mortality among
patients admitted to hospital with COVID-19 is
under researched; however, two previous publications
have shown that theCharlson index of comorbidity is a
good predictor of mortality in cases of severe COVID-
19-related infections.13,14
In the UK, following the evidence from the initial
reports showing a higher risk of adverse outcomes
associated with certain conditions, a Shielded
Patient List was created.10 This list included a
record of vulnerable patients with specific conditions
or treatments thought to be at high risk of complica-
tions from COVID-19.15 Individuals having any con-
dition on the Shielded Patient List received advice to
avoid or minimise non-essential contacts. However,
no special recommendation was made to patients
with multimorbidity if they did not have any of
those conditions. Understanding how multimorbidity
impacts on patients admitted to a hospital due to
severe COVID-19 is important to help clinicians
with the management of these patients and provide
meaningful analysis for public health policymakers
around the world.9,16–18
We aimed to investigate how multimorbidity,
Shielded Patient List conditions and demographic
factors including age, sex and socio-economic depriv-
ation in patients hospitalised with COVID-19 was
associated with an increased mortality risk during
the first wave (28 February to 22 September 2020)
of the pandemic in Scotland. Specific research ques-
tions were: (1) What was the prevalence of multimor-
bidity and how it varied by age, sex and deprivation
among the population admitted to the hospital with
COVID-19?, (2) What was the association between
COVID-19-related mortality and multimorbidity,
and how it varied by age, sex and deprivation? and
(3) Was there an increased risk of mortality from
COVID-19 if patients were on the Shielded Patient
List and multimorbid?
Materials and methods
Study design and data sources
Patients admitted to Scottish hospitals with COVID-
19 were identified through the electronic
communication of surveillance in scotland (ECOSS)
and hospital admissions (SMR01) database. We
included patients with an admission within 14 days
of PCRþ ve test or validated by the presence of ICD-
10 codes U07.1 and U07.2. Using routinely collected
secondary care data, we developed a cohort of 4684
patients hospitalised in Scotland due to COVID-19
for the first time between 28 February 2020 and 22
September 2020. We retrieved Scottish national data
on outpatient appointment and attendances
(SMR00), hospital admissions (SMR01),
Community Prescriptions (PIS), Electronic
Communication of Surveillance in Scotland and
Death Registrations and Demography.19 The data-
sets used the Community Health Index (CHI) num-
bers that are present on all healthcare encounters in
Scotland to link the datasets, which were then anon-
ymised and made available on the National Data Safe
Haven platform.19,20
Variables
Exposure. The primary independent variable was the
presence of multimorbidity. To identify the condi-
tions of each patient for multimorbidity analysis,
we used data from routinely collected health records
from 1 April 2006. To define the presence of multi-
morbidity, we used all 31 conditions included in the
Elixhauser comorbidity Index21,22 and the eight con-
ditions from nine listed in the Shielded Patient List15
(further details on all the conditions can be found in
Supplementary Material). We were unable to identify
pregnant women from the available data who were
advised to shield. Levels of multimorbidity were cate-
gorised as ‘no multimorbidity’ (no recorded condition
or only one condition) and ‘multimorbidity’ (for
2þ recorded conditions). Additionally, we also car-
ried out an analysis of ‘complex multimorbidity’,
defined as the presence of four or more recorded
conditions.
Outcome. We identified mortality among patients
admitted to hospital for COVID-19 as reported via
National Records of Scotland death certificates
coded for COVID-19 on the death certificate (U07.1
and U07.2 ICD-10 codes) or death within 28 days of
a positive COVID-19 test.
Other variables
Other explanatory variables included in the model
based on their known relationship to multimorbidity
and death were patient’s sex (male or female), age
group (<50, 51–65, 66–80 and >80 years) and the
level of deprivation measured by quintiles (most
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deprived to least deprived) based on the Scottish
Index of Multiple Deprivation attributed to the
home postcode of the patient. We merged under
18 s with the age group 19–50 to safeguard against
potential unintended disclosure risk for individuals
due to small numbers.
Statistical analysis
Descriptive statistics reported the prevalence of mul-
timorbidity among individuals hospitalised due to
COVID-19 and its variation by different demo-
graphic characteristics. Numbers and proportions
within each group of interest were reported.
A logistic regression model, with clustering of
patients within the hospital, was used to assess the
risk of death among COVID-19 hospitalised patients
and the presence of multimorbidity among these
patients. An univariable regression model was used
to analyse the risk of mortality against the presence
of multimorbidity, presence in the Shielded Patient
List and demographic characteristics including age,
sex and deprivation. A multivariable regression
model adjusting for all the significant aforementioned
factors was used. Adjusted odds ratio (AOR), and
95% confidence interval (CI) were reported.
Although outcomes were expected to be relatively
common, reporting OR was still a valid approach.23
We also analysed a random-effects model to check for
clustering of patients within the hospital.
Since previous studies associated mortality with
increasing comorbidities and presence in the
Shielded Patient List,24 we explored the interaction
between them and the prediction on mortality.
Subsequently, a multivariable logistic regression
model tested for interaction between the presence of
multimorbidity and the presence in the Shielded
Patient List, in the prediction of mortality.
Ethics, software and dissemination
We obtained approval from Scotland A Research
Ethics Committee (Ref: 20/SS/0028) and Public
Benefit and Privacy Panel for Health and Social
Care (HSC-PBPP). R Studio statistical software
(R version 3.60)25 was used for all the analysis and
visualisation. All the R codes will be published on
Github.
Reporting guidelines
Guidelines from Reporting of studies Conducted using
Observational Routinely-collected Data (RECORD)
extended from the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE)
was used to communicate the findings.
Figure 1. Distribution of individuals with no multimorbidity, multimorbidity and complex multimorbidity within each age groups.
The proportion of no multimorbidity in each age band decreased with age while that of complex multimorbidity increased. For
visualisation, no multimorbidity was 1 conditions, multimorbidity was described as 2–3 conditions, and complex multimorbidity
was 4þ.
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Results
Of the 6512 individuals hospitalised between
28 February 2020 and 22 September 2020 in
Scotland due to COVID-19, we could link and valid-
ate information for 4684 (71.9%) individuals and
thus included all these individuals in the study. The
median age of patients was 71 years (interquartile
range 57–82). Most patients admitted to hospital
with COVID-19 were affected by multimorbidity
(2713, 57.9%) and almost half of this group had com-
plex multimorbidity (1248, 26.6%). There were 1330
(28.4%) recorded deaths. Among individuals who
died, more than three quarters (989, 74.4%) had mul-
timorbidity and almost four in 10 had complex multi-
morbidity (503, 40.3%).
Description of COVID-19-related hospitalisation
and prevalence of multimorbidity
The proportion of patients with multimorbidity
increased with age from 26.5% in the under 50 age
group to 76.7% among patients aged 80 years or
higher (see Figure 1), but there was little difference
by sex (Table 1). There were higher levels of
Table 1. Distribution of multimorbidity by patients characteristics for hospital admissions due to COVID-19.
Number of conditions (n (%))
Characteristics n No multimorbidity (1) Multimorbidity (2þ) Complexmultimorbidity (4þ)
Hospitalisation 4684 1971 (42.1) 2713 (57.9) 1248 (26.6)
Age group (years)
<50 688 506 (73.5) 182 (26.5) 55 (8.0)
51–65 1234 709 (57.5) 525 (42.5) 182 (14.7)
66–80 1457 452 (31.0) 1005 (69.0) 476 (32.7)
80þ 1305 304 (23.3) 1001 (76.7) 535 (41.0)
Sex
Male 2531 1087 (42.9) 1444 (57.1) 647 (25.6)
Female 2151 883 (41.1) 1268 (58.9) 601 (27.9)
Missing 2
Shielding group
Yes 1759 324 (18.4) 1435 (81.6) 792 (45.0)
No 2925 1647 (56.3) 1278 (43.7) 456 (15.6)
Deprivation
Most 1320 483 (36.6) 837 (63.4) 409 (31.0)
2 1058 436 (41.2) 622 (58.8) 299 (28.3)
3 833 339 (40.7) 494 (59.3) 214 (25.7)
4 778 357 (45.9) 421 (54.1) 177 (22.8)
Least 679 349 (51.4) 330 (48.6) 147 (21.6)
Missing 16 – – –
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multimorbidity and complex multimorbidity (81.6%,
45.0%) for people in the Shielded Patient List than in
the non-shielding group (43.7%, 15.6%). Lastly,
there was also social patterning of multimorbidity
where it was more prevalent in people from deprived
areas.
Mortality related to multimorbidity and other
patient characteristics
COVID-19-related mortality was high among
patients with multimorbidity (989, 36.5%, see
Table 2). Over half of these patients had complex
multimorbidity with a higher proportion of mortality
in this group (503, 40.3%). Mortality increased with
age from 4.4% for patients under the age of 50
to 46.1% in patients aged 80 years or older (see
Figure 2). Almost half of the hospitalised patients
were males, and they had a higher mortality
(32.2%) in comparison to females (24.0%). Among
patients in the shielding group and non-shielding
group, the proportion of mortality was 36.8% and
23.4%, respectively.
Association of mortality with multimorbidity
Patients with multimorbidity, increasing age, males
and present in Shielded Patient List were associated
with increased risk of death. Controlling for age, sex
and deprivation, it was observed that patients with
multimorbidity were at higher risk of death than
those without it (AOR 1.48, 95%CI 1.26–1.75,
p< 0.001) (see Table 3). Mortality increased with
age significantly and was almost 15 times
(AOR15.34, 95% CI 10.50–23.26, p< 0.001) higher
among those aged 80 years or more than those aged
19 to 50 years.
Since no death was reported in the under 18 age
groups, it was excluded from the modelling analysis
and to safeguard against potential unintended
disclosure risk for individuals. We also grouped
patients by the hospital in which they were admitted
to check for any random effect, and there were
very small random effects (variance: 0.008, CI:
0.006–0.010).
Interaction analysis
Since shielding had a strong positive association with
multimorbidity, we explored interaction effects
between multimorbidity and being in the shielding
group but found no association with a multiplicative
effect on risk of mortality among the cohort (see
Supplementary Material Table 1).
Table 2. Distribution of hospitalisation and mortality by








No (1) 1971 (42.1) 341 17.3
Yes (2þ) 2713 (57.9) 989 36.5
4þ 1248 (26.6) 503 40.3
Age group
<50 688 (14.7) 30 4.4
51–65 1234 (26.3) 173 14.0
66–80 1457 (31.1) 526 36.1
80þ 1305 (27.9) 601 46.1
Sex
Male 2531 (54.0) 814 32.2
Female 2151 (45.9) 516 24.0
Missing 2 (0.1) –
Shielding group
Yes 1759 (37.6) 647 36.8
No 2925 (62.4) 683 23.4
Deprivation
Most 1320 (28.2) 389 29.5
2 1058 (22.6) 291 27.5
3 833 (17.8) 263 31.6
4 778 (16.6) 214 27.5
Least 679 (14.6) 171 25.2
Missing 16 (0.3) <5 –
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Discussion
Our analysis showed that in patients admitted to
hospital due to COVID-19, 6 out of 10 had multi-
morbidity, with almost half of this group having
complex multimorbidity. The presence of multimor-
bidity was associated with a 50% increase in the risk
of death, after adjusting for age, sex, social class and
shielding status. Patients who had been advised to
shield were at higher risk of mortality from COVID-
19 than those not shielding and this was independ-
ent of the effect of multimorbidity.26–28
Strengths of the work included the prospective
data collection in a standardised manner across a
number of hospitals. However, one limitation of
the study is that data were not available on the eth-
nicity of all the patients, so it was not included as a
confounder. The use of the Elixhauser comorbidity
index based on electronic health records21,22 com-
bined with information on conditions from the
shielding list15 provided a robust and transparent
mechanism to determine multimorbidity. Although
only selecting the aforementioned comorbidities
based on previous secondary care admissions is a
limitation of the study, they incorporate a core set
of disorders for multimorbidity measurement that
covers a wide range of conditions including a total
of 39 different conditions. Moreover, using the sec-
ondary care data, we were able to capture the most
severe patients within the multimorbidity spectrum.
The level of multimorbidity will change dependent on
which list of conditions is included and the conse-
quences of multimorbidity also change with different
combinations and severity of conditions, which we
did not explore in this analysis. Another limitation
of the study is that primary care data were not avail-
able, which may have resulted in underestimates of
the prevalence of multimorbidity as it was based on
secondary care data.
Our findings reinforce that the presence of multi-
morbidity is associated with the risk of death among
individuals hospitalised with COVID-19. Some pre-
vious work have shown the association of few indi-
vidual comorbidities (which are generally Shielded
Patient List conditions) with adverse out-
comes,16,13,29 we included an expanded list of 39
conditions. Although deprivation was not found to
be a significant factor for patients with worse out-
comes in this analysis, among the patients admitted
to the hospital, the proportion increased with the
deprivation index. Some previous studies have
reported that individuals in the Shielded Patient
List were at a very high risk of severe outcomes.24,30
In addition, we also found that these conditions
were a risk factor independent of the presence of
multimorbidity.
This study suggests that multimorbidity should be
considered as an independent risk factor of worse
outcomes in the case of contracting COVID-19.
This population should thus be prioritised when pro-
tective and preventive measures are planned like
expanding shielding advice or vaccination programs.
Figure 2. Variation of mortality proportion by age groups for individuals with no multimorbidity, multimorbidity and complex
multimorbidity. For visualisation, no multimorbidity was 1 conditions, multimorbidity was described as 2–3 conditions, and
complex multimorbidity was 4þ.
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Social support should also be provided to this popu-
lation for them being able to protect themselves.
Moreover, the results also indicate that the advice
given to shielding patients based on individual con-
ditions could also be extended to those with multi-
morbidity and especially complex multimorbidity as
they have similarly high levels of mortality. The effect
of age on mortality for patients with COVID-19 is
well established, but our analysis of multimorbidity by
age suggests younger people with high levels of multi-
morbidity may be at similar levels of risk as older
patients.
Conclusion
Multimorbidity is a risk factor for mortality in
patients admitted to hospital with COVID-19 and
the risk increases with higher levels of multimorbid-
ity. Patients who were advised to shield to protect
themselves from COVID-19 were also at higher risk
of mortality, and this is independent of multimorbid-
ity. We suggest that the advice given to shielding
patients could be extended to those with multimor-
bidity and especially complex multimorbidity as they
have similarly high levels of mortality.
Table 3. Odds ratio of univariable and multivariable models for risk of death adjusted for patient characteristics including
multimorbidity.
Factors Unadjsuted odds ratio (95% CI, p-value) Adjusted odds ratio (95% CI, p-value)
Multimorbidity
No 1.00 1.00
Yes 2.70 (2.34–3.11, p< 0.001) 1.49 (1.26–1.75, p< 0.001)
Age group
19–50 1.00 1.00
51–65 3.41 (2.29–5.09, p< 0.001) 3.14 (2.09–4.72, p< 0.001)
66–80 11.82 (8.07–17.33 p< 0.001) 9.41 (6.35–13.96, p< 0.001)
80þ 17.93 (12.23–26.30, p< 0.001) 15.34 (10.31–22.80, p< 0.001)
Sex
Female 1.00 1.00
Male 1.50 (1.32–1.71, p< 0.001) 1.72 (1.49–1.98, p< 0.001)
Shielding
No 1.00 1.00
Yes 1.89 (1.66 – 2.15, p< 0.001) 1.31 (1.13–1.52, p< 0.001)
Deprivation
Most 1.24 (1.00–1.54, p¼ 0.055) 1.36 (1.08–1.71, p¼ 0.010)
2 1.13 (0.91–1.42, p¼ 0.270) 1.19 (0.94–1.51, p¼ 0.152)
3 1.35 (1.07–1.70, p¼ 0.011) 1.42 (1.11–1.82, p¼ 0.005)
4 1.11 (0.88–1.41, p¼ 0.389) 1.18 (0.91–1.52, p¼ 0.205)
Least 1.00 1.00
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